<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124850</url>
  </required_header>
  <id_info>
    <org_study_id>VRXP-A106</org_study_id>
    <nct_id>NCT02124850</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab</brief_title>
  <official_title>A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol VRXP-A106 will enroll patients with Stage II-IVA head and neck cancer patients who&#xD;
      will be treated with surgical resection. Cetuximab and motolimod (Cohort 1); and cetuximab,&#xD;
      motolimod, and nivolumab (Cohort 2) will be administered for a 3-4 week period before&#xD;
      surgery. The primary objective of the study is to determine the extent to which the&#xD;
      administration of neoadjuvant motolimod plus cetuximab and motolimod plus cetuximab and&#xD;
      nivolumab modulates immune biomarkers (NK, mDC and T cell activation as well as tumor&#xD;
      infiltration and serum cytokines) in peripheral blood and head and neck cancer tumors. An&#xD;
      exploratory objective of the study is to assess whether modulation of biomarkers as described&#xD;
      above can predict anti-tumor response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 28, 2014</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in immune biomarkers including FcγR genotype, NK activation, tumor infiltration and serum cytokines, mDC, T cell activation, and tumor-antigen specific cytotoxic T lymphocyte induction.</measure>
    <time_frame>change from baseline to up to 4 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Anti-tumor response</measure>
    <time_frame>Change from baseline to pre-surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: motolimod plus cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: motolimod, cetuximab, and nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motolimod</intervention_name>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>VTX-2337</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated stage II, III, or IVA histologically or cytologically confirmed&#xD;
             squamous cell carcinoma of the head and neck&#xD;
&#xD;
          -  Primary tumors of the oral cavity, oropharynx, hypopharynx, or larynx&#xD;
&#xD;
          -  Macroscopic complete resection of the primary tumor must be planned&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate hematologic, renal and hepatic function&#xD;
&#xD;
          -  Have signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who fail to meet inclusion criteria&#xD;
&#xD;
          -  Primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary&#xD;
             tumors&#xD;
&#xD;
          -  Prior severe infusion reaction to a monoclonal antibody&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Evidence of distant metastasis&#xD;
&#xD;
          -  Any other malignancy active within 5 years except for non-melanoma skin cancer or&#xD;
             carcinoma in situ of the cervix, DCIS or LCIS of the breast&#xD;
&#xD;
          -  Prior history of head and neck cancer&#xD;
&#xD;
          -  Prior therapy with motolimod, nivolumab, or other agents targeting PD-1/PD-L1&#xD;
&#xD;
          -  Prior therapy targeting the EGFR pathway&#xD;
&#xD;
          -  Acute hepatitis, known HIV, or active uncontrolled infection&#xD;
&#xD;
          -  Patients with active autoimmune disease&#xD;
&#xD;
          -  History of uncontrolled cardiac disease within prior 6 months&#xD;
&#xD;
          -  Uncontrolled peptic or gastric ulcer disease, or gastrointestinal bleeding within&#xD;
             prior 6 months&#xD;
&#xD;
          -  Active alcohol abuse or other illness or circumstance that carries a likelihood of&#xD;
             inability to comply with study treatment and follow-up or otherwise compromise the&#xD;
             study's objectives&#xD;
&#xD;
          -  Treatment with a non-approved or investigational drug within 30 days prior to Day 1 of&#xD;
             study treatment&#xD;
&#xD;
          -  Live vaccine within 30 days of planned start of study therapy&#xD;
&#xD;
          -  History of pneumonitis or interstitial lung disease&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to nivolumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>https://clincancerres.aacrjournals.org/content/clincanres/early/2017/11/28/1078-0432.CCR-17-0357.full.pdf</citation>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

